Clinical Trial Update: Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of TKI 258 in combination with Xeloda (capecitabine) and oxaliplatin in advanced colorectal cancer and gastric cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• TKI 258
• Xeloda (capecitabine)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Colorectal Cancer, Gastric Cancer | Phase 1 | Status: TERMINATED